A woman of forty-two with early-onset Parkinsonism and a father who developed similar signs in his sixties is referred for genomic testing. The clinician's question is specific: is there a monogenic cause that would change her treatment and that her two children should be offered testing for? The request form has a tick box for 'neurological, adult' and a free-text field, in which the registrar writes 'Parkinsonism, query genetic'.
The laboratory runs its adult neurology analysis, reports a variant of uncertain significance in a gene for a childhood-onset dystonia, and closes the case. The question about her children is never answered, because the laboratory never saw it.
What the field knows
Genomic testing has not removed the clinical reasoning that preceded it. Shashi and colleagues (2014), reviewing the diagnostic evaluation of undiagnosed patients before and alongside exome sequencing, found that the traditional clinical assessment, the history, the examination and the framing of a differential, still determined much of what the test could find, because it determined what was looked for and how the result was read. Wright, FitzPatrick and Firth (2018), reviewing paediatric genomics, describe diagnosis as an iterative conversation between clinic and laboratory in which the phenotype, the candidate and the interpretation are revised together.
The laboratory standards assume that conversation is written down. The ACMG standards for clinical sequencing (Rehm et al., 2013) require the requisition to carry the clinical indication and the reason for testing, and require the report to address that indication. The ACGS best practice guidelines (Ellard et al., 2020) tie the evidence weighting for a variant to the specificity of the phenotype and the question asked, since a variant in a gene that explains the referral is read differently from one in a gene that does not.
The reanalysis guidance (Deignan et al., 2019) makes the same point from the other end. Whether a case should be reopened depends on what it was meant to answer. New evidence about a gene unrelated to the clinical question is a different event from new evidence about the gene the question was about, and a laboratory cannot tell them apart without the question.
The question also has parts that a phenotype does not carry. Who is the test for, the patient or the family? What decision waits on the result: a treatment, a reproductive choice, an end to further investigation? What would count as an answer, and what would count as enough to stop? These are the terms under which the case can be called finished, and they are the terms most often left in the clinician's head.
Where practice breaks
The request form asks for a diagnosis category and a phenotype, and it gets a category and a phenotype. The question that produced the referral is compressed into whichever box is nearest, and the laboratory, which can only answer what it is asked, answers the box. 'Parkinsonism, query genetic' names a topic and leaves the question out.
Without the question, the laboratory cannot scope the analysis. Should the adult neurology gene list be used, or the Parkinsonism list, or the exome? Should a variant of uncertain significance in a childhood dystonia gene be reported? Each is a judgement the laboratory makes by policy because it has no case-specific instruction, and the policy may be right for most referrals and wrong for this one.
Without the question, nobody can tell when the case is done. The report answers what the laboratory took the question to be. The clinician reads it against the question they actually had, finds it does not answer it, and either re-refers with the same form or lets the matter drop. The children in the opening case are not offered testing, because the report said nothing about them, because the request said nothing about them.
The question drifts over the life of a case. A case opened to explain a child's seizures becomes, as the child grows, a case about reproductive risk for the parents. At reanalysis the laboratory reopens the original question, which no longer matters as much, and does not know the new one exists.
Counsellors see the cost most directly. They are the people who sit with the family after the report and translate a document written to one question into answers to another, and they are the people the family rings when the report has nothing to say about the thing they asked. Much of that work is repair for a sentence that was never written on the request.
How Tulparus handles it
Every case opens with a clinical question in words, written by the clinician or counsellor, separate from the phenotype. The question has structure the workbench can use: who it is for, what decision waits on it, and what would count as an answer. It is versioned like the rest of the case, so that when the question changes the earlier one is kept and the change is dated.
The question scopes the investigation. Candidates are generated broadly, and the hypothesis comparison shows for each candidate whether it addresses the question as asked: a gene for a childhood-onset condition in a woman of forty-two is shown as a poor fit to the question, whatever its fit to the phenotype terms, and the mismatch is named. The scope is also recorded: which gene lists or which breadth of analysis were applied and why, so that a later reader knows what the answer covers. The next steps proposed are the ones that move the question, so that for the woman above a segregation study with her father's sample, if one can be obtained, is proposed before anything else.
Sign-off is against the question. A report cannot be issued without a statement of how far the question was answered: answered, partly answered with what remains, or not answered and why. The children's testing in the opening case would appear as an open item that the report has to address, because the question named them.
At reanalysis, the question is the first thing the reviewer sees, and a new piece of knowledge is matched against the question as well as against the variants. If the question has been superseded, the clinician is asked to confirm the current one before the case is reopened on the old.
What you can do tomorrow
The question is already being asked in clinic. The work is to write it down where the laboratory will read it.
- On every request, add two sentences in the free text: what you want to know, and what you will do with the answer. The laboratory can scope an analysis from that.
- Say who the result is for. If the family's reproductive or predictive testing depends on it, the laboratory should know before it decides what to report.
- When a report comes back, read it against your question rather than against the form, and write the gap into the notes if there is one.
- When the question changes, tell the laboratory. A case reopened on the wrong question is time spent on a result nobody is waiting for.
Sources
- Shashi V, McConkie-Rosell A, Rosell B, et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. Genetics in Medicine, 2014.
- Wright CF, FitzPatrick DR, Firth HV. Paediatric genomics: diagnosing rare disease in children. Nature Reviews Genetics, 2018.
- Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing. Genetics in Medicine, 2013.
- Ellard S, Baple EL, Callaway A, et al. ACGS best practice guidelines for variant classification in rare disease 2020. Association for Clinical Genomic Science, 2020.
- Deignan JL, Chung WK, Kearney HM, Monaghan KG, Rehder CW, Chao EC. Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2019.